Suven Pharmaceuticals Q1 Results FY26: Q1 PAT Falls 35.15% to ₹48.88 Crore; Revenue Up 12.55% YoY

Suven Pharmaceuticals Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

Suven Pharmaceuticals Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Suven Pharmaceuticals Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Suven Pharmaceuticals clocked Q1 FY26 consolidated revenue of ₹549.31 crores vs ₹488.08 crores. 
• On the profit front, Suven Pharmaceuticals earned a consolidated PAT of ₹48.88 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹75.37 crore. 
• Consolidated PAT fell for the first quarter of FY26, was 35.15% YoY, and revenue rose 12.55% YoY. 
• Suven Pharmaceuticals clocked Q1 FY26 standalone revenue of ₹483.58 crores vs ₹488.08 crores. 
• On the profit front, Suven Pharmaceuticals earned a standalone PAT of ₹52.57 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹75.45 crore. 
• As per the standalone figures, the quarterly PAT of Suven Pharmaceuticals has decreased by 30.32%, and revenue has decreased by 0.92% YoY.

Suven Pharmaceuticals Share Price Performance

On the opening bell of 14th August 2025, the shares of Suven Pharmaceuticals opened at ₹969.45 per share. However, the initial gains are wiped out as of now, and Suven Pharmaceuticals shares are trading at ₹917.90 per share, lower than their opening price. 

Considering the long-term performance, Suven Pharmaceuticals shares have yielded close to -14.11% returns in the past 1 year, and 5-year returns stand at -15.69%. Over the maximum timeframe, the Suven Pharmaceuticals share provided -15.69% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Suven Pharmaceuticals shares after thorough research. 

What Analysts Expect Post Q1 Results?

As Suven Pharmaceuticals has posted robust Q1 results for FY26, analysts are expecting positive trends in its share price. As per the analysts, Suven Pharmaceuticals’s share price could reach ₹1,885.00 per share in the coming year, and in downtrends, the share price could hit the level of ₹1,022.00 per share. However, one must ignore the risk of volatility in the stock market and invest in Suven Pharmaceuticals shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Also Read : Bayer Cropscience Q1 Results FY26: Q1 PAT Soars 9.64% to 278.70 Crore; Revenue Jumps 17.36% YoY

Recent Articles

Max Healthcare Q1 Results FY26: Q1 PAT Rises 30.35% to ₹307.97 Crore; Revenue Up 31.41% YoY

Minda Corporation Q1 Results FY26: Q1 PAT Rises 1.73% to ₹65.31 Crore; Revenue Up 16.23% YoY

Bharat Dynamics Q1 Results FY26: Q1 PAT Rises 154.30% to ₹18.35 Crore; Revenue Up 29.69% YoY

Elitecon International Q1 Results FY26: Q1 PAT Rises 349.99% to ₹20.41 Crore; Revenue Up 301.98% YoY

Elgi Equipments Q1 Results FY26: Q1 PAT Rises 17.58% to ₹85.60 Crore; Revenue Up 8.19% YoY

Aavas Financier Q1 Results FY26: Q1 PAT Rises 10.41% to ₹139.23 Crore; Revenue Up 15.70% YoY

Regaal Resources IPO GMP: Day 2 IPO Live Updates